NCT04534205 2026-02-12
AHEAD-MERIT
BioNTech SE
Phase 2/3 Recruiting
Clinical Trials
3 trialsNCT06697301 2025-11-12
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
Eikon Therapeutics
Phase 2/3 Recruiting
NCT06947928 2025-10-14
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
TuHURA Biosciences, Inc.
Phase 2/3 Recruiting